4Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase Ⅲ study [J]. J Clin Oncol, 2001, 19 (21) : 4097-4106.
5Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26 (12) : 2006-2012.
6Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study [J]. J Clin Oncol, 2007, 25 (30) : 4779-4786.
7Kurt M, Aksoy S, Guler N. Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients? [J]. Acta Oncol, 2006, 45 (5) : 625-626.
8Yamashita K, Yada H, Ariyoshi T. Neurotoxic effects of alpha-fluorobeta-alanine (FBAL) and fluoroacetic acid (FA) on dogs [J]. J Toxicol Sci, 2004, 29 (2) : 155-166.
9Muneoka K, Shirai Y, Yokoyama N, et al. 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine [J]. Int J Clin Oncol, 2005, 10 (6) :441-443.
10Fischel JL, Formento P, Ciccolini J, et al. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes [J]. A nticancer Drugs, 2004, 15 (10) : 969-974.
